Clinical Trials Logo

Diffuse Intrinsic Pontine Glioma clinical trials

View clinical trials related to Diffuse Intrinsic Pontine Glioma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05063357 Withdrawn - DIPG Clinical Trials

131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma

Start date: March 2022
Phase: Phase 1
Study type: Interventional

Omburtamab is a murine IgG1 monoclonal antibody, recognizing CD276 (also known as B7- H3). Omburtamab is 131I-labeled at designated radio pharmacies and will be provided as a final radiolabeled product to treatment site. The proposed intervention includes surgical placement using standard stereotactic techniques of a small caliber cannula into the tumor in the pons followed by positive pressure infusion (i.e. CED) of 131I-omburtamab. Iodine-131 conjugated omburtamab (131I-omburtamab) administered via the intracerebroventricular route for the treatment of metastatic CNS neuroblastoma was shown to be tolerable and improve survival. Furthermore, 124I-omburtamab administered by convection enhanced delivery (CED) was shown to have a tolerable safety profile in an ongoing dose escalation trial (in doses up to 4mCi) in patients with diffuse pontine gliomas that have not progressed following external beam radiation therapy. The aim of this trial is to determine the efficacy and safety of 131I-omburtamab in patients with DIPG that have not progressed following external beam radiation therapy.

NCT ID: NCT04051047 Withdrawn - Glioma Clinical Trials

Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma

Start date: November 30, 2019
Phase: Early Phase 1
Study type: Interventional

The primary aim of this study is to determine the presence of gemcitabine in childhood diffuse midline gliomas (DMG) (previously classified as diffuse intrinsic pontine glioma [DIPG]) after systemic treatment with the drug.

NCT ID: NCT03632317 Withdrawn - Glioma Clinical Trials

A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas

Start date: October 2019
Phase: Phase 2
Study type: Interventional

This phase 2 trial will evaluate the activity of Panobinostat in combination with Everolimus for children with gliomas harboring H3.1 or H3.3K27M mutation, including newly diagnosed high-grade glioma or DIPG (diffuse intrinsic pontine glioma) after radiation (stratum A) and recurrent/progressive glioma (grade II-IV, including DIPG) (stratum B).